a b s t r a c t
The ␤-adrenergic blocker and 5-HT 1A receptor antagonist pindolol has been combined with selective serotonin reuptake inhibitors (SSRIs) in patients with depressive and anxiety disorders to shorten the onset of the clinical action and/or increase the proportion of responders. The results of a previous study have shown that pindolol potentiates the panicolytic effect of paroxetine in rats submitted to the elevated T-maze (ETM). Since reported evidence has implicated the 5-HT 1A receptors of the dorsal periaqueductal gray matter (DPAG) in the panicolytic effect of antidepressants, rats treated with pindolol (5.0 mg/kg, i.p.) and paroxetine (1.5 mg/kg, i.p.) received a previous intra-DPAG injection of the selective 5-HT 1A antagonist, WAY-100635 (0.4 g) and were submitted to the ETM. Pretreatment with WAY-100635 reversed the increase in escape latency, a panicolytic effect, determined by the pindolol-paroxetine combination. These results implicate the 5-HT 1A receptors of the DPAG in the panicolytic effect of the pindolol-paroxetine combination administered systemically. They also give further preclinical support for the use of this drug combination in the treatment of panic disorder.
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Selective serotonin (5-HT) reuptake inhibitors (SSRIs) have been successfully used for the treatment of several anxiety disorders, including generalized anxiety (GAD) [13, 20] , panic disorder (PD) [25] , in addition to depressive disorders [29] . Although antidepressant treatments are effective, they have a slow onset of action, resulting in a delay of several weeks before clinical improvement becomes significant [26] . They may also produce an initial exacerbation of anxiety symptoms, especially in PD [5] . An additional problem is the resistance of nearly 30% of treated patients to this therapeutic approach [28] . Clinical studies have shown that the association of a ␤-adrenergic blocker such as pindolol, which is also a 5-HT 1A receptor antagonist, generally hastens the antidepressant effect [1, 18] , intensifies the panicolytic effect of SSRIs in treatment-resistant panic patients [11, 38] and further reduces panic symptomatology [36, 37] . These effects have been attributed to the blockade of somatodendritic 5-HT 1A receptors [10, 21] , but criticisms on this view have been raised [3, 24] . In addition, negative results have also been reported [4, 30] which have been interpreted on the basis of methodological differences among studies, such as the use of suboptimal doses of pindolol (for further details see [24] ).
A recent study performed in this laboratory has shown that the combination of ineffective doses of pindolol and of the SSRI paroxetine significantly increase escape latency in rats submitted to elevated T-maze (ETM), indicating a selective panicolytic effect [23] . The ETM is an animal model that measures both inhibitory avoidance and one-way escape in the same rat, tasks which have been related to the GAD and PD, respectively [9] .
On the basis of preclinical [35] and clinical [8] results, serotonergic mechanisms that control defensive behavior in the dorsal periaqueductal gray matter (DPAG) have been implicated in the pathophysiology of PD and in the therapeutic action of antidepressant drugs. Particularly, 5-HT 1A and 5-HT 2A receptors localized in this brain structure have been shown to mediate panicolytic drug effects in two animal models of panic, namely the ETM and the electrical stimulation of the DPAG [16, 22, 35] .
To evaluate the participation of the 5-HT 1A receptors of the DPAG in the panicolytic effect of the combination of pindolol and paroxetine, we have presently verified whether a previous injection of the 5-HT 1A antagonist WAY-100635 into the DPAG would reduce the panicolytic effect of the systemic administration of the pindolol-paroxetine combination measured in the ETM. Open access under the Elsevier OA license.
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Male Wistar rats (n = 44) weighing 230-250 g were housed in groups of four or five and given free access to food and water. Temperature was kept at 22 ± 1 • C, and a 12-h light-dark cycle (lights on at 07:00) was maintained throughout the experiments. The experimental procedures adopted had been approved by the UEM Ethics Committee (062/2007-CEEA), and follow the Biomedical Research Involving Animals (CIMS) recommendations (Geneva, 1985) .
The ETM was made of wood and had three arms of equal dimensions (50 cm × 12 cm). One arm, enclosed by 40 cm high walls, was perpendicular to two opposed open arms. To avoid falls, the open arms were surrounded by a 1-cm high Plexiglas rim. The whole apparatus was elevated 50 cm above the floor. The open-field test was performed in a wooden round box (70 cm diameter) with walls 30 cm high. Luminosity on the maze arms or on the circular arena center was 60 lux.
The following drugs were used:
Maleate (WAY-100635; Sigma, USA). Drugs were dissolved in a solution containing sterile saline with 2% Tween 80, except for WAY-100635, which was dissolved in sterile saline. All drugs were freshly prepared, 30 min before injections.
Rats anesthetized with ketamine (70 mg/kg, Virbac, Brazil) and xylazine (12 mg/kg, Vetbrands, Brazil) by the intramuscular route, associated with local anesthesia (2% xylocaine with adrenaline, Bravet laboratory, Brazil), were positioned in a stereotaxic frame (David-Kopf). A stainless-steel guide cannula (12 mm long; outer and inner diameter 0.6 mm and 0.4 mm, respectively) was implanted 1.4 mm above the DPAG for microinjection. The stereotaxic coordinates from the Paxinos and Watson [17] with reference to bregma were: posterior −6.6 mm, lateral 2.0 mm, and deep 3.6 mm, at an angle of 22 • . The stainless-steel guide cannula was fixed to the skull with stainless-steel screws and selfpolymerizing acrylate resin, and closed with a stainless-steel wire to prevent obstruction. Following this procedure, the animals were treated with an antibiotic preparation by the intramuscular route (benzylpenicilin and streptomycin, Fort Dodge, Brazil) to prevent infection.
On the fifth and sixth days after the surgery, animals were gently handled for 5 min and, on the sixth day, were exposed to one of the open arms of the ETM for 30 min. A wooden barrier mounted on the border of the maze central area and the open arm's proximal end isolated this arm from the rest of the maze. It has been shown that prior exposure to one of the open arms of the maze decreases the latencies to leave this arm on a later trial and renders the escape task sensitive to chronic antidepressant treatment, probably due to habituation to the open arm, eliminating the inhibitory interference of novelty on escape performance [27, 32] .
On the seventh day, animals were tested in both the ETM and the open-field. After randomization, rats were administered intraperitoneally (i.p.) with pindolol (5.0 mg/kg, Pin) or vehicle solution (Veh), 20 min before paroxetine (1.5 mg/kg, Par) or Veh, and 50 min later were injected into the DPAG with either WAY-100635 (0.4 g) or saline. Thus, the following groups were formed: Veh + Veh i.p./Sal DPAG (control; n = 12), Veh + Veh i.p./WAY DPAG (n = 11), Pin + Par i.p./Sal DPAG (n = 10), Pin + Par i.p./WAY DPAG (n = 11). After 40 min from the intra-DPAG injection, animals were submitted to the behavioral tests. The behaviors were scored by an experimenter blind to the treatments.
For intra-DPAG injections (WAY-100635 or saline), a needle (0.3 mm outer diameter) was introduced through the guide cannula until its tip was 1.4 mm below the cannula end. A volume of 0.2 l was injected over a period of 2 min (0.1 l/min) using a 10 l microsyringe (Hamilton 701-RN, USA) attached to a microinfusion pump (KD Scientific, USA). The intra-cerebral needle was removed 1 min after the injection was finished.
The test in the ETM was initiated by the inhibitory avoidance task. To this end, each animal was placed at the distal end of the enclosed arm of the ETM facing the intersection of the arms. The time taken by the rat to leave this arm with the four paws was recorded (baseline latency). The same measurement was repeated in two subsequent trials (avoidance 1 and 2) at 30-s intervals. Following avoidance training (30 s), rats were placed at the end of the same, previously experienced open arm, and the latency to leave this arm with the four paws was recorded for three consecutive times (escape 1, 2 and 3) at 30 s inter-trial intervals. A cut-off time of 300 s was established for the avoidance and escape latencies. Thirty seconds after being tested in the ETM, each animal was placed for 5 min in the open-field for the evaluation of locomotion. The total distance traveled was recorded by a video tracking system (Ethovision; Noldus, Holland). The behavioral tests have been conducted from 08:00 to 13:00 h.
After the experiments, animals were anesthetized with sodium pentobarbital (Cristália, Brazil) by the i.p. route, and their brains were perfused intracardially with saline solution (0.9% NaCl) followed by 10% formalin solution before being removed and fixed in 10% formalin. Brain slices of 50 m were sectioned by means of a microtome in order to localize the site of the drug injection, according to the Paxinos and Watson's atlas [17] . Only animals with injection sites located inside the DPAG were included in the statistical analysis (see Fig. 1 ).
Repeated-measures analysis of variance (RM-ANOVA) was used to analyze both avoidance and escape data, with drug treatment as the independent factor and trial as the repeated measure. When appropriate, one-way ANOVA followed by the post hoc Duncan's multiple comparison tests was used. Locomotor activity data were analyzed by one-way ANOVA followed by the same Duncan's test. Differences between groups were considered significant if p ≤ 0.05. Fig. 1 depicts the sites of drug injections of animals tested in the current study. The effect of drug treatments on escape performance can be seen in Fig. 2 The post hoc test revealed that the pindolol-paroxetine combination significantly increased escape 1 latency, and that the intra-DPAG injection of WAY-100635 abolished this effect (p < 0.01).
The drug treatments employed did not interfere with either inhibitory avoidance acquisition or locomotion in the open-field (see Table 1 ).
The findings confirm previously reported results [23] showing that the acute administration of the ␤-adrenergic and 5-HT 1A receptor antagonist pindolol combined with the SSRI paroxetine has a panicolytic effect, indicated by the significant increase of escape latency in the ETM. More importantly, they additionally show that previous intra-DPAG microinjection of the 5-HT 1A receptor antagonist WAY-100635 counteracts the panicolytic effect of this drug combination.
Since the different treatments presently used did not significantly modify the total distance traveled by the animals in the open-field the observed effects in the ETM are unlikely to be due to non-specific alterations in motor function.
Several reported results have shown that pindolol blocks 5-HT 1A autoreceptors of the raphe nuclei more effectively than 5-HT 1A postsynaptic receptors located in limbic areas [14, 21] . This property may be responsible for the blockade of the SSRI-induced inhibition of 5-HT cell firing and potentiation the SSRIs therapeutic effect [2] . Yet, autoradiographic and positron emission tomography (PET) studies have questioned this view, since their results have shown that at clinically-used doses pindolol (7.5 mg/day) occupies only a moderate number of 5-HT 1A receptors in the human brain [3, 24] .
Although the mechanism of the clinical action of the pindolol-SSRI combination is a matter of debate, preclinical evidence has clearly shown that pindolol potentiates the increase of extracellular levels of 5-HT determined by SSRIs in different brain regions [6, 12, 15, 21] , although there is one study that found no such effect of selective ␤ 1 or ␤ 2 -adrenergic antagonists in the frontal cortex [12] .
The finding that blockade of 5-HT 1A receptors in the DPAG prevent the panicolytic effect of the combined administration of pindolol and paroxetine is consonant with reported evidence showing that chemical stimulation of the dorsal raphe nucleus enhances 5-HT extracellular levels in the DPAG, measured by in vivo microdialysis [31] , and that pretreatment with an intra-DPAG injection of WAY-100635 antagonizes the anti-escape effect of this raphe stimulation in the ETM [19] . In addition, previously reported results have shown that 5-HT 1A (and 5-HT 2A ) receptor agonists injected into the DPAG inhibit the escape response generated by electrical stimulation of the same brain area [7, 16, 22] as well as intermediate the panicolytic effect of chronic treatment with SSRIs, including imipramine, fluoxetine, sertraline, measured in the ETM [33] [34] [35] .
In summary, the results show that the intra-DPAG injection of the selective 5-HT 1A receptor antagonist WAY-100635 counteracts the anti-escape effect of the systemic administration of a pindololparoxetine combination in the ETM. Therefore 5-HT 1A receptors located in the DPAG are likely to mediate the panicolytic-effect of this drug combination. These results also give further preclinical support for the use of this drug combination in the treatment of PD.
